Last updated on June 2019

A Phase 1b Study of INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors Carcinoma


Brief description of study

The purpose of this study is to determine the safety, preliminary evidence of clinical activity, and recommended Phase 2 dose (RP2D) of INCMGA00012 in combination with other agents that may improve the therapeutic efficacy of anti-PD-1 monotherapy.

Clinical Study Identifier: TX223523

Find a site near you

Start Over

HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA

3400 CIVIC CENTER BLVD PHILADELPHIA, PA United States
  Connect »

UNIVERSITY OF CHICAGO MEDICAL CENTER

Located in: CHICAGO, IL United States
  Connect »

RUTGERS CANCER INSTITUTE OF NJ

Located in: NEW BRUNSWICK, NJ United States
  Connect »

ROSWELL PARK CANCER INSTITUTE

Located in: BUFFALO, NY United States
  Connect »

UNIVERSITY OF FLORIDA - SHANDS CANCER CENTER

Located in: GAINESVILLE, FL United States
  Connect »

YALE NEW HAVEN HOSPITAL

Located in: NEW HAVEN, CT United States
  Connect »